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http://dx.doi.org/10.1016/j.stemcr.2016.04.003SUMMARYHuman pluripotent stem cells (hPSCs) exist in heterogeneous micro-environments with multiple subpopulations, convoluting fate-
regulation analysis. We patterned hPSCs into engineered micro-environments and screened responses to 400 small-molecule kinase
inhibitors, measuring yield and purity outputs of undifferentiated, neuroectoderm, mesendoderm, and extra-embryonic populations.
Enrichment analysis revealed mammalian target of rapamycin (mTOR) inhibition as a strong inducer of mesendoderm. Dose responses
ofmTOR inhibitors suchas rapamycinsynergizedwithBoneMorphogeneticprotein4 (BMP4) andactivinA toenhance theyield andpurity
of BRACHYURY-expressing cells. Mechanistically, small interfering RNA knockdown of RAPTOR, a component of mTOR complex 1,
phenocopied the mesendoderm-enhancing effects of rapamycin. Functional analysis during mesoderm and endoderm differentiation re-
vealed thatmTORinhibition increasedtheoutputofhemogenicendothelial cells3-fold,withaconcomitantenhancementofbloodcolony-
forming cells. These data demonstrate the power of ourmulti-lineage screening approach and identify mTOR signaling as a node in hPSC
differentiation to mesendoderm and its derivatives.INTRODUCTION
Human pluripotent stem cells (hPSCs) and their differenti-
ated derivatives offer the exciting opportunity to develop
tools to study and treat human diseases. However, robust
and reproducible control of hPSC fate remains chal-
lenging. Small molecules offer one approach to control
hPSC fate, and the discovery and characterization of these
compounds can be facilitated by cell-based phenotypic
high-throughput screening (HTS). Emerging data from
hPSC assays has revealed variable and contradictory
observations, even with matched cell lines and protocols
(Haibe-Kains et al., 2013). Although the factors underlying
this variability are not completely known, population
context has been identified as a main contributor to assay
inconsistency (Snijder et al., 2012). Spatially heteroge-
neous (Peerani et al., 2007) micro-environmental factors
such as endogenous ligands, extra-cellular matrix proteins
(ECMPs), and cell subpopulations are strong regulators of
hPSC fate. Specifically, spatial cell distribution has been
shown to affect hPSC self-renewal (Maherali and Hoched-
linger, 2008), differentiation trajectories in both normal
and patient-derived cells (Cai et al., 2009; Chambers
et al., 2009), and disease phenotypes (Sun et al., 2012).
Consequently, robust assays that combine defined cul-
ture conditions with comprehensive analysis of cell re-
sponses to exogenous cues are needed. To this end, we
developed a chemically defined cell patterning-based
high-throughput (HTP) assay, engineering colony size,
local cell density, medium composition, and substrate forStem
This is an open access article under the Crapid and robust measurement of hPSC fate responses to
exogenous cues (Nazareth et al., 2013). We applied the
assay to screen a library of kinase inhibitors for effects on
four early hPSC fates. For each compound, the change in
yield and purity in the resulting pluripotent, neuroecto-
derm (NE), mesendoderm, and extra-embryonic popula-
tions were simultaneously tracked, allowing for estimation
of selection and induction events. Our analysis identified
mammalian target of rapamycin (mTOR) inhibitors, such
as rapamycin, as having a strong mesendoderm-inducing
effect on hPSCs. Rapamycin was subsequently shown to
synergize with bone morphogenetic protein 4 (BMP4)
and activin A to enhance BRACHYURY induction more
than 3-fold, an effect that propagated to equivalent
enhancements of hemogenic endothelium and blood
progenitor cells. This study demonstrates the advan-
tages of controlling micro-environmental parameters and
measuring multiple subpopulation outputs in parallel on
PSC fate screening assays. This strategy should enhance dis-
covery in more complex and predictive multi-cell popula-
tion drug-screening assays.RESULTS
A Kinase Inhibitor Screen of hPSCs Revealed Lineage-
Specific Regulators
We previously developed a 48-hr hPSC screen that em-
ploys control of spatial cell patterning to configure the
hPSC micro-environment for rapid and robust responseCell Reports j Vol. 6 j 679–691 j May 10, 2016 j ª 2016 The Authors 679
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. HTS of Small-Molecule Regu-
lators of hPSC Pluripotency, Primitive
Streak, NE, and Extra-embryonic/Other
Cell-Fate Decisions
(A) Assay design. hPSCs are micro-patterned
on micro-contact printed 200-mm diameter
extracellular matrix proteins (ECMP) circles
in 96-well plates. Control or base medium
with test compounds is added to each well.
After 48 hr, imaging is performed and single-
cell OCT4 and SOX2 expression levels are
quantified.
(B) Subpopulation purity and high yield
are measured to determine inductive effects
of compounds. Diagram demonstrates the
changes in composition and purity of the
‘‘pink’’ cell population.
(C) Compound distribution ranked by induc-
tion efficiency of pluripotency, NE, primitive
streak, and extra-embryonic/other cell fates.
(D) Sample composite colony images from
controls and selected responders stained for
DNA (DAPI, blue), OCT4 (green), and SOX2
(red). BMP4 is the OCT4SOX2 control, CM is
the OCT4+SOX2+ control, FGF2 + SB431542 is
theOCT4SOX2+ control, andBMP4+ activin A
is the OCT4+SOX2 control. Colony outlined
with dotted white line. Scale bar, 100 mm.
(E) Calcein (viability) staining of unfixed
cells at 48 hr treated with hit compounds.
Non-viable control treated with methanol.
Colonies are outlined with a dotted white
line. Scale bar, 200 mm.
(F) 67 putative hit compounds ranked by
increasing viability. n = 3 independent bio-
logical replicates. Error bars indicate SD.
See also Figure S1.to exogenous cues (96mCP assay) (Nazareth et al., 2013)
(Figure 1A). Single-cell OCT4 and SOX2 costaining enables
simultaneous classification of pluripotent (OCT4+SOX2+),
NE (OCT4SOX2+), mesendoderm (OCT4+SOX2), and
extra-embryonic/other (OCT4SOX2) cell fates. This
platform can be used to screen test factor effects on yield
(percentage) and purity (absolute number of cells) of
each subpopulation per colony using in-house software
(Figure 1B).
We applied this platform to screen a collection of 400
small-molecule kinase inhibitors at two concentrations
(0.2 mM and 1 mM). To ensure a significantly large sample
size, we performed further analysis only on compounds
which yielded >800 imaged cells per well, resulting in
707 unique conditions including five controls on each
plate: base medium (blank), PSC supporting mouse embry-
onic fibroblast (MEF)-conditioned (CM), NE inducing
transforming growth factor b (TGF-b) inhibitor and fibro-680 Stem Cell Reports j Vol. 6 j 679–691 j May 10, 2016blast growth factor 2 (FGF2) (TiF), mesendoderm inducing
BMP4 with activin A (BA), and extra-embryonic inducing
BMP4. The overall distributions of the compounds with
respect to each subpopulation indicated that mesendo-
derm and extra-embryonic/other inducing compounds
were underrepresented (Figure 1C). Control conditions
showed high reproducibility across plates (Figure S1A).
Calculation of the Z0 factor, a statistical parameter used to
compare HTP assays (Zhang et al., 1999), for the pattern-
based (Z0 = 0.94)and non-pattern-based (Desbordes et al.,
2008) (Z0 = 0.29, p < 0.01) assays supported the rationale
for controlling micro-environments to improve robustness
(Figures S1B and S1C). Sample images of control conditions
and select responders are shown in Figure 1D. Viability of
endpoint cells was confirmed at 48 hr using calcein and
Hoechst staining (Figures 1E and 1F).
To visualize factor effects on responding population cell
yield and purity, we measured the percentage and average
temsirolimus
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Figure 2. Pathway Enrichment Analysis
(A) Increase in PSC purity (%OCT4+SOX2+)
versus increase in yield (number of OCT4+
SOX2+ cells per colony) obtained from 712
unique treatments. Values from blank were
subtracted (graph origin represents base
medium alone). Thresholds for purity and
yield were used to classify ‘‘pluripotency re-
sponders.’’ Arrow indicates a sample re-
sponding compound.
(B and C) Similar analysis as in (A) to classify
(B) NE and (C) mesendoderm responders.
Dotted lines outline the regions classified as
responders.
(D) Enrichment in PSC responders (shown in
Figure 1D). p Values were obtained for each
target, using the hypergeometric distribu-
tion, and shown in log base 10. Threshold
corresponds to p = 0.001.
(E and F) Similar analysis as in (D) for (E) NE
and (F) mesendoderm responders.
(G) Two-dimensional hierarchical clustering
of subpopulation yield and purity data across
treatments. Left: sample similarity tree, with
samples clustered. Enhanced primitive streak
cluster is in purple, PSC cluster in blue, and
NE cluster in red. Right: detailed view of
enhanced primitive streak cluster, indicating
compound name, concentration, and re-
ported kinase targets indicated in red.
See also Figures S2 and S3; Table S2.number of cells of each subpopulation per colony per well.
For example, to visualize effects on the PSC population we
subtracted the percentage and number of OCT4+SOX2+
cells obtained in the blank to obtain DOCT4+SOX2+ (%)
and DOCT4+SOX2+ (number of cells per colony), respec-
tively (Figure 2A). Based on the subpopulation positive
controls, we set thresholds for yield and purity to obtain
a list of ‘‘responders.’’ Similar visualizations are shown
for NE (OCT4SOX2+) (Figure 2B) and mesendoderm
(OCT4+SOX2) (Figure 2C). Enlarged plots of the threshold
regions showing compound names of responders are
shown in Figure S2. Visual inspection of responding com-
pounds confirmed the expected yield and purity effects
(Figure 1D). Based on these results, we sought to determine
whether responding compounds were enriched for specific
inhibitor targets.
Specific Kinase Inhibitor Targets for NE and
Mesendoderm Induction Identified
To identify fate-modulating pathways enriched in our
library, we performed a hypergeometric test to obtain
p values for the enrichment of each kinase target in the
PSC, NE, and mesendoderm responder groups (five mostenriched targets are shown in Figures 2D–2F; count of
unique compounds for each kinase target is shown in
Figure S3A; count of kinase targets in responders and total
screen is shown in Table S1). For the PSC-enhanced clus-
ter no target family was statistically enriched, indicating
that the tested kinase inhibitors do not robustly rescue
hPSCs from differentiation in the blank lacking exoge-
nous FGF2 and activin A (Vallier et al., 2005). This sug-
gests that, in contrast to differentiation, exogenous
pathway agonists, or a combination of inhibitors, may
be required to maintain pluripotency in vitro (Tsutsui
et al., 2011). For NE responders we obtained the highest
enrichment for small molecules targeting the ERK/MEK
pathway (p = 2.9 3 105) (Figure 2E), as well as a high
enrichment (p = 0.001) of small molecules targeting
TGF-b superfamily type I activin receptor-like kinase
(ALK) receptors ALK4, ALK5, and ALK7. Inhibition of
TGF-b signaling has been well established to result in
hPSC differentiation to NE (Smith et al., 2008; Vallier
et al., 2004). We previously observed low levels of endog-
enous TGF-b signaling in the 96mCP assay, which likely
contributes to lower than expected significance of ALK4/
5/7 inhibitors. Lastly, in the mesendoderm respondersStem Cell Reports j Vol. 6 j 679–691 j May 10, 2016 681
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Figure 3. PSC and NE Subpopulation
Screen Analysis
(A) Subpopulation percentages from all
screened MEK/ERK inhibitors, ranked by PSC
percentage response.
(B) Subpopulation cells per colony from all
screened MEK/ERK inhibitors, ranked by PSC
percentage response.
(C) The MEK inhibitor PD-0325901 increases
the percentage of early NE and decreases the
percentage of PSCs. *p < 0.001, significant
difference from blank control; n R 3 inde-
pendent biological replicates.
(D) MEK inhibitor PD-0325901 does not
increase the number of early NE. *p < 0.01,
significant difference from blank control;
nR 3 independent biological replicates.
Error bars indicate SD. See also Figure S4.we found the highest enrichment for mTOR inhibitors
(p = 8.1 3 1011) (Figure 2F).
In addition to target enrichment analysis, two-dimen-
sional hierarchical clustering (707 conditions, eight out-
puts, 5,656 data points) revealed several distinct pheno-
type clusters (Figure 2G, left). A cluster of compounds
that enhanced PSC (blue dendrogram) also contained the
CM control (Figure S3B). Similarly, a cluster that enhanced
NE (red dendrogram) also contained the TiF control
(Figure S3C). The few compounds that enhancedmesendo-
derm (purple dendrogram) clustered with two mesendo-
derm induction controls, BA and BA with FGF2 (BAF) (Fig-
ure 2G, right). In this cluster, 53% of the compounds
targeted mTOR and no other kinase was targeted by more
than one compound. Enrichment analysis of the three
clusters revealed identically significantly enriched path-
ways as our threshold-based method (Figure S3D), further
confirming the ERK/MEK and mTOR enrichments found
in the screen. Based on these results we sought to further
validate the ERK/MEK and mTOR results.
ERK/MEK Inhibition Induces hPSC Differentiation to
NE in a BMP-Dependent Manner
Analyzing all the ERK/MEK inhibitors in our library, we
observed a general increase in the percentage of NE cells
at the expense of PSCs, with no changes in total cell num-
ber (Figures 3A and 3B). To further investigate the effect of
MEK inhibition, we retested PD0325901 and found a
significant reduction in PSC yield and increase in NE fre-
quency (both p < 0.001) (Figure 3C), but found no signifi-
cant increase in NE cells per colony induced relative to
the blank control (p = 0.43), indicative of selection (Fig-
ure 3D). Reports aremixed on the effects ofMEK inhibition
(via PD0325901) on neural induction, and there is strong
evidence that variability in endogenous factors such as682 Stem Cell Reports j Vol. 6 j 679–691 j May 10, 2016BMP has hindered interpretation of these previous results
(Greber et al., 2011).
To further investigate, we performed a meta-analysis of a
previous dataset of the response of a panel of cell lines to a
set of conditions including blank medium, PD0325901,
and TiF, using the 96mCP assay (Nazareth et al., 2013).
This analysis demonstrated that PD0325901 and TiF varia-
bly induce early NE in a cell-line- and passage-dependent
manner (Figure S4A). Next, to determine the depen-
dencies of PD0325901-induced NE on other pathways,
we compared the effect of PD0325901 on NE induction
in the blank, with BA, or with 17 other single factors that
are agonists or antagonists of major developmental path-
ways. When BMP4 was added with PD0325901, NE induc-
tion was reduced from 95% to less than 0.5% (p < 0.002),
confirming that NE is exceptionally sensitive to BMP4,
strengthening the possibility that endogenous BMP4 abol-
ishes NE induction (Figure S4B). Notably, PD0325901 in-
duction of NE was affected by other factors, including
FGF2, activin A, TGF-b, insulin-like growth factor 1, and
heregulin b1, congruent with previous proposals that inhi-
bition of MEK, BMP, and TGF-b signaling (Greber et al.,
2011) or dual BMP and TGF-b signaling (Kim et al., 2010)
may indeed robustly induce NE regardless of variations in
endogenous signaling. Together, these data confirm that
NE induction via MEK inhibition alone is highly variable
across hPSC lines, support our hypothesis that this induc-
tion is sensitive to BMP inhibition, and demonstrate that
our platform can reveal subtle molecular perturbations of
PSC fate.
mTOR Inhibitors Dose-Dependently Induce
Mesendoderm in hPSCs
Our analysis indicated a strong effect of mTOR inhibition
on mesendoderm induction. Conflicting reports show
that mTOR inhibition inhibits PSCs and enhances serum-
mediated differentiation toward mesoderm and endo-
derm (Zhou et al., 2009), or may enhance the purity of
pluripotent cells (Easley et al., 2010). To validate that
mTOR inhibitors enhance mesendoderm induction, we
screened nine mTOR inhibitors at both 1 mM and 0.1 mM,
and screened eight inhibitors of additional pathways
implicated in hPSC regulation. Ranking the compounds
according to level of effect on mesendoderm induction
(%OCT4+SOX2), the mTOR inhibitors clearly separated
from the others and the majority of conditions tested
significantly enhanced the percentage of OCT4+SOX2
cells relative to blank serum-free (SF) medium alone (p <
0.05) (Figure 4A). Rapamycin at 1 mM was the strongest
responder of all the conditions, comparable with the BA
control. Rapamycin binds to FKBP12 and inhibits the ki-
nase activity of mTOR complex 1 (mTORC1), which con-
tains mTOR and RAPTOR (Sabers et al., 1995). A separate
complex containing mTOR and RICTOR (mTORC2) is
thought to be rapamycin insensitive, although this is
cell-line and context dependent (Lamming et al., 2012).
In contrast to rapamycin and its derivatives such as tem-
sirolimus and everolimus, which only target mTORC1,
next-generation dual mTORC1/2 inhibitors have been
developed, such as AZD-8055 and KU-63794. Notably,
within the 18 mTOR inhibitor treatments (nine com-
pounds at two concentrations), the top half of ranked
responders are enriched for compounds only targeting
mTORC1 (p < 0.005).
To further validate the effect of mTOR inhibitors on
hPSCs, we performed ten-point dose curves of two mTOR
inhibitors, rapamycin and AZD-8055, and again measured
the four early OCT4/SOX2 subpopulations. As expected,
both compounds increased the percentage of mesendo-
derm cells in a dose-dependent manner (Figure 4B). Sur-
prisingly, a bimodal response to rapamycin was observed
in the PSC response, where at 0.001 and 0.01 nM there
was a moderate but significant enhancement of the per-
centage and number of PSCs. This enhancement was not
seen at concentrations above 0.1 nM, wheremesendoderm
induction peaks at 0.1 mM (Figure 4C). The yield, and not
just percentage, of PSCs are enhanced by low concentra-
tions of rapamycin (Figure 4D). This bimodal response
was seen with two additional replicates of rapamycin (not
shown) but was not seen with AZD-8055, which may indi-
cate that the mechanism is via mTORC1 inhibition (Fig-
ure 4D). Additional studies are required to understand
this effect more completely.
mTOR Inhibitor-Mediated Induction ofMesendoderm
Is BMP-Receptor and TGF-b-Receptor Dependent
To gain insight into the mechanism behind mTOR inhibi-
tion inducing mesendoderm in hPSCs, we screened 14agonists and antagonists of early development signaling
pathways, alone and with rapamycin (Figures 4E and S5).
TGF-b1 and FGF2 moderately enhanced rapamycin-
inducedmesendoderm. Inhibition of either phosphatidyli-
nositol-3-kinase (using LY-294002), a downstream effector
of mTOR implicated in mesendoderm differentiation
(Singh et al., 2012), or Wnt (using IWP4) did not signifi-
cantly alter the effect of rapamycin. The effects of rapamy-
cin were abolished by the BMP type I receptor (ALK2/3)
inhibitor LDN-193189, MEK inhibitor PD-032591, and
TGF-b receptor (ALK4/5/7) inhibitor SB-431542. Consis-
tent with our results, MEK inhibition has been shown to
divert differentiation from mesendoderm (Yu et al.,
2011), indicating that mTOR inhibition is insufficient
to overcome this effect. The LDN-193189 and SB-431542
results imply that rapamycin’s effect on mesendoderm
is dependent on BMP and TGF-b receptor-mediated
signaling, which are both required for hPSC differentiation
toward mesendoderm (Vallier et al., 2009). Addition of
either (or both) of these inhibitors to rapamycin, relative
to rapamycin alone, results in loss of the OCT4+SOX2
population, no difference in the OCT4+SOX2+ population,
and amoderately enhanced SOX2+OCT4 population (Fig-
ure S5A), with no change in the total number of cells per
colony (Figure S5B).
Based on the blocking effects of SB-431542 and LDN-
193189,wereasonedthat rapamycin,which inducesmesen-
doderm alone in SF-defined medium, may act additively or
synergistically with endogenous TGF-b/BMP signaling. We
therefore generated a rapamycin dose curve with (rap+BA)
and without (rap+BA) exogenous BMP4 (10 ng ml1) and
activin A (100 ngml1), and analyzedmesendoderm induc-
tion by BRACHYURY (Zhang et al., 2008) expression. The
percentage and number of BRACHYURY+ cells in both
rap+BA and rap+BA increased in a rapamycin dose-depen-
dent manner. The maximum percentage of BRACHYURY+
cells achieved with rapamycin alone (19%) was comparable
with the percentage achieved with BA alone (18%); how-
ever, rap+BA resulted in a more than 3-fold increased yield
of BRACHYURY+ (57%) compared with BA alone (p <
0.005) (Figure 4F). The number of BRACHYURY+ cells per
colony was also enhanced in rap+BA relative to BA alone
by3.8-fold (p< 0.005) (Figure4G). Sample images are shown
in Figure 4H. Similar trends were observed in dose curves
generated from non-patterned hPSCs with rapamycin, or
an alternative mTOR inhibitor (temsirolimus) and a BA
background (Figures S5C–S5F).
Knockdown of RAPTOR Phenocopies the
Mesendoderm-Inducing Effects of Rapamycin
Functionally, mTOR operates as part of two protein com-
plexes, mTORC1 and mTORC2 (reviewed in Sabatini,
2006), which are differentially regulated by upstreamStem Cell Reports j Vol. 6 j 679–691 j May 10, 2016 683
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Figure 4. mTOR Inhibitors in Defined Medium Upregulate Mesendoderm via TGF-b and BMP Pathways
(A) Nine mTOR inhibitors in the OICR library were tested at 1 and 0.1 mM. Additional inhibitors of kinases implicated in early development
but not targeting mTOR (‘‘other inhibitors’’) were also tested. Small molecules were ranked by effect magnitude to separate mTOR inhibitors
from others. *p < 0.01, **p < 0.001 compared with blank; n = 3 independent biological replicates.
(B) Ten-point dose curves of mTOR inhibitors rapamycin and AZD-8055 show a dose-dependent increase of % mesendoderm. *p < 0.05
compared with blank control; n = 3 independent biological replicates. Blank and BA response shown as reference lines.
(legend continued on next page)
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(B) The effect of siRNA on BRACHYURY
expression. siRNA was applied in different
medium conditions as noted to non-
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blue) and BRACHYURY expression (red), with
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Error bars indicate SD.signals and have different downstream effectors. Although
rapamycin was long thought to inhibit mTORC1, recent
studies revealed that rapamycin can also inhibit mTORC2
in a cell-type-dependent manner (Lamming et al., 2012).
To examine the role of each mTOR complex in rapa-
mycin-induced mesendoderm differentiation, we targeted
RAPTOR (mTORC1 specific) and RICTOR (mTORC2
specific) with small interfering RNA (siRNA). PSCs were
seeded in pluripotency medium with siRNA against either
RAPTOR (siRAPTOR) or RICTOR (siRICTOR). Two days
after seeding, the medium was exchanged with fresh(C) Ten-point dose curves of rapamycin show a bimodal increase in %
pendent biological replicates.
(D) Ten-point dose curves of rapamycin and AZD-8055 effect on numb
but not AZD-8055. *p < 0.05 compared with blank (0 rapamycin); n =
(E) 14 factors (ligands and small molecules) targeting early develop
teractions. n = 3 independent biological replicates. *p < 0.05, compa
(F) Dose curves of rapamycin performed alone and with BMP4 (10 n
of BRACHYURY+ cells per well was quantified. *p < 0.05 and **p < 0.00
n = 3 independent biological replicates. Response to blank and BMP4
(G) Same experiment as in (F) showing the number of BRACHYURY cel
condition without rapamycin; n = 3 independent biological replicate
(H) Images of cells stained for DNA (DAPI, blue) and BRACHYURY ex
dotted white line. Scale bar, 200 mm.
Error bars indicate SD. See also Figure S5.medium under three conditions (+blank, +rapamycin,
or +BA), in the presence of siRNA. Analysis of OCT4 and
SOX2 expression was conducted at day 4 (Figure 5A). In
blank medium, siRAPTOR enhanced the percentage of
mesendoderm (OCT4+SOX2) cells relative to control
scrambled siRNA (siCTRL) (p < 0.0005), but siRICTOR
had no significant effect. Addition of both siRAPTOR and
siRICTOR gave a phenotype similar to siRAPTOR alone,
and gave rise to a significantly higher percentage of mesen-
doderm cells than siRICTOR alone (p < 0.05). In the pres-
ence of rapamycin, siRAPTOR again had a significant effectPSCs. *p < 0.05 compared with blank (0 rapamycin); n = 3 inde-
er of PSCs per colony at subnanomolar concentrations of rapamycin
3 independent biological replicates.
ment pathways tested alone and with rapamycin to screen for in-
red with blank + rapamycin condition.
g ml1) and activin A (100 ng ml1) showing average percentage
5 both compared with the equivalent condition without rapamycin;
and activin A alone (‘‘BA’’) are shown as reference lines.
ls per colony. *p < 0.05, **p < 0.005 compared with the equivalent
s.
pression (red), with treatments as indicated. Colony outlined with
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(p < 0.0005), and siRICTOR was not significantly different
from siCTRL. This result indicates that rapamycin (at
0.1 mM) is not completely inhibiting mTORC1. In the pres-
ence of BA, siRAPTOR also enhances the percentage of
OCT4+SOX2 cells relative to siCTRL (p < 0.0005). Interest-
ingly, in this medium condition siRICTOR also enhanced
the percentage of OCT4+SOX2 (p < 0.0005), indicating
that the effect of mTORC2 inhibition is dependent on
TGF-b/BMP signaling. Focusing on the BA conditions, we
repeated the siRNA assay and stained for BRACHYURY. As
expected, siRAPTOR significantly enhanced both percent-
age (Figure 5B) and number (Figure 5C) of BRACHYURY+
cells, similarly to rapamycin treatment. Sample images
are shown in Figure 5D. No effect was observed from
siRICTOR on BRACHYURY induction, indicating that the
effect of rapamycin on BRACHYURY induction is primarily
through mTORC1 and not mTORC2. These results also
indicate a divergence between the OCT4+SOX2 readout
and BRACHYURY expression and further corroborate that
rapamycin is acting via inhibition of mTOR signaling,
not via non-specific effects.
mTOR Inhibition Impedes Endoderm and Enhances
Mesoderm Differentiation
Based on the observation that mTOR inhibition en-
hances the purity and number of mesendoderm cells, we
investigated the effect of rapamycin on specific down-
stream mesoderm and endoderm progenitors. We first
differentiated hPSCs, in either BA or rap+BA (0.1 mM) for
42 hr, and assessed various markers of NE (PAX3, PAX6),
mesendoderm (MIXL1, BRACHYURY), mesoderm (MEIS1,
MYB), cardiac precursor (MESP1, NKX2.5, PDGFRa),
hematopoietic (RUNX1), definitive endoderm (EOMES),
primitive endoderm (GATA6, AFP), and trophectoderm
(HAND1) lineages via qRT-PCR (Figure S6A). In general, ra-
pamycin supplementation enhanced all differentiated
lineage markers, with the exception of HAND1, a marker
of trophectoderm, and EOMES, associated with definitive
endoderm (DE).
We next specifically tested the effect of rapamycin on DE
induction. Differentiation to DE is a multi-step process
including a 1-day induction phase (D0) where cells are
exposed to activin A (100 ng ml1) and the glycogen
synthase kinase 3b (GSK3b) inhibitor CHIR99021 (CHIR,
2 mM) (Rezania et al., 2012). We tested various concen-
trations of rapamycin at D0 and measured the resulting
FOXA2+SOX17+ DE at day 5. Although DE differentiation
protocols can be extremely efficient in specific cell lines
(Nostro et al., 2011), differentiation efficacy is known to
vary greatly between different cell lines (Nazareth et al.,
2013). Thus we tested four cell lines with varying DE induc-
tion efficiencies and demonstrated that rapamycin dose-
dependently reduced DE induction (%FOXA2+SOX17+686 Stem Cell Reports j Vol. 6 j 679–691 j May 10, 2016cells) in PDX1, HES2, and HES3-RUNX1-GFP cell lines,
and had no effect onH9DE induction (Figure 6A). These re-
sults show that rapamycin does not enhance endodermdif-
ferentiation and may be specific to mesoderm induction.
Next, to test the effect ofmTOR inhibition onmesoderm-
derived lineages, we evaluated hematopoietic differentia-
tion of hPSCs. During embryogenesis, hematopoietic cells
are derived from specialized endothelial cells called hemo-
genic endothelium (HE), isolated using vascular endothe-
lial cadherin (VECAD) and CD34 expression (Eilken et al.,
2009). To track HE induction in our studies, hPSC (HES3-
RUNX1-GFP cell line) aggregates were cultured in chemi-
cally defined medium (Pick et al., 2007) in the presence
of rapamycin (0.1 mM) from day 0 to 2 and VECAD+CD34+
expression was assessed throughout an 8-day time course.
Controls were cultured in the absence of rapamycin. The
CD34+VECAD+ expression profile revealed that rapamycin
addition from day 0 to day 2 enhances both purity and
yield of HE (Figures 6B and 6C). Note that day-6 rapamy-
cin-generated CD34+VECAD+ cells were also CD73 and
CD184 (Figures S6B and S6C), further confirming their
HE phenotype (Ditadi and Sturgeon, 2015). The maximum
CD34+VECAD+ percentage reached in controls was 10% ±
4%, falling within the range of previously reported results
in the literature (Ditadi and Sturgeon, 2015), whereas in
rapamycin 30% ± 11% purity was attained (p < 0.05) (Fig-
ure 6D). Rapamycin addition also enhanced HE purity
in the HES2 cell line (Figure S6D), demonstrating that our
observations are not limited to the HES3-RUNX1-GFP
line. Moreover, rapamycin conditions exhibited a 4-fold
increase in CD34+VECAD+ cells on day 6 and a 2.5-fold
increase on day 8 (99% confidence intervals shown in
Figure 6E). Furthermore, kinase insert domain receptor
(KDR, also known as vascular endothelial growth factor re-
ceptor 2) expression, an earlymarker of all blood cells (Sha-
laby et al., 1997), nearly doubled on day 4 in rapamycin
(Figure S6E). To functionally assess whether early rapamy-
cin treatment enhances blood progenitor induction, we
seeded cells from cultures initiated either in the presence
or absence of rapamycin in methylcellulose colony-form-
ing cell (CFC) assays (Csaszar et al., 2012). A 1.7-fold in-
crease (p < 0.05) in the number of CFCs per 105 cells
was obtained in rapamycin-treated conditions (202 ± 42
CFCs [mean ± SEM]) compared with control conditions
(117 ± 26 CFCs) (Figures 6F and S6F). Additionally, gene
expression analysis at days 0, 1, and 2 confirmed that
rapamycin addition significantly increased the expression
of BRACHYURY (p < 0.002) and MIXL1 (p < 0.0002)
(Figure S6G). These results demonstrate that rapamycin
treatment during days 0 to 2 of hematopoietic differentia-
tion of hPSCs enhances the blood progenitor phenotype.
A summary of our findings on the role of mTORC1 in
hPSC lineage-fate decisions is presented in Figure 6G.
AB C D
E
F G
Figure 6. mTOR Inhibition Enhances HE
and Blood Induction
(A) Four hPSC cell lines were differentiated
to DE using a 5-day protocol and analyzed for
FOXA2+SOX17+ expression. Rapamycin was
added as indicated during the D0 phase. n =
3 independent biological replicates. Error
bars indicate SD.
(B) Representative flow cytometry scatter-
plots of VECAD and CD34 expression in day 8
hPSC-derived HE with (top) and without
(bottom) rapamycin.
(C) Time course showing VECAD+CD34+ cells
from days 1–8 of differentiation showing
percentage (top) and number per well
(bottom) with and without rapamycin.
N indicates number of independent biolog-
ical replicates. Error bars indicate SD.
(D) Comparison of the maximum VECAD+
CD34+ percentage obtained with or without
rapamycin. *p < 0.05; n = 3 independent
biological replicates. Error bars indicate SD.
(E) Comparison of the fold increase in
number of CD34+VECAD+ achieved with ra-
pamycin relative to without rapamycin, on
days 6 and 8. n = 3 independent biological
replicates. Error bars indicate 99% confi-
dence interval.
(F) CFC comparison of definitive blood
obtained with and without rapamycin. n = 3
independent runs of the HES2 (one repli-
cate) and RUNX1-GFP (two replicates) cell
lines. Error bars indicate SD. *p < 0.05
(paired Student’s t test).
(G) Summary of the role of rapamycin in
hPSCs.
See also Figure S6.DISCUSSION
We have applied an engineered micro-environment based
HTS platform to screen a kinase inhibitor library simulta-
neously for regulators of PSCs, NE, and mesendoderm.
Small-molecule control of cell fate is attractive for scale-up
purposes, and a focused library could be instrumental in
elucidating endogenous regulators of hPSC fate decisions.
In line with a previous screen (Desbordes et al., 2008), we
foundno single compound able tomaintain long-termplu-
ripotency, indicating that exogenous pathway agonists or
possibly combinations of small-molecule inhibitors may
be required for hPSC maintenance. Our multi-lineage
readout enabled the discovery of specific pathways endoge-
nously activated inhPSCs amenable to small-molecule con-trol of lineage-specific differentiation. Patterning enabled a
more rapid (48 hr versus 7 days) assay and robust response
than non-pattern-based screens (Desbordes et al., 2008).
Additionally, the short assay duration limits the number
of emergent subpopulations, allowing simultaneous detec-
tion of these subpopulations to be tracked by OCT4 and
SOX2 costaining. In conjunction with cell-number read-
outs, selection and induction events can be reasonably
discriminated.
Our analysis revealed that mTOR inhibitors added alone
to SF-defined medium can induce mesendoderm, and our
follow-up studies confirmed that rapamycin enhances the
formation of HE and blood progenitors. Ten-point dose
curves revealed a bimodal effect where rapamycin at low
concentrations mildly enhances the purity and numberStem Cell Reports j Vol. 6 j 679–691 j May 10, 2016 687
of OCT4+SOX2+ PSCs, and higher concentrations reduce
the OCT4+SOX2+ population and enhance mesendoderm
differentiation. These results reconcile two previous
studies: in line with Easley et al. (2010) we observe no nega-
tive effect on pluripotency of rapamycin at low concentra-
tions, and in line with Zhou et al. (2009) we observe loss of
pluripotency and induction of mesendoderm at higher
concentrations. In contrast to Zhou et al., we found that ra-
pamycin strongly inhibits DE induction. This difference
may be serum mediated or cell-line dependent. Addition-
ally, emerging evidence suggests that separate induction
mechanisms may confer distinct mesoderm/endoderm
subtype potentials (Mendjan et al., 2014).
Although both GSK3b and mTOR inhibition appear
to enhance mesendoderm, rapamycin-treated hPSCs
appear to generate significantly higher frequencies of
CD34+VECAD+CD73 HE phenotype cells compared
with CHIR99021 (GSK3b inhibitor)-treated conditions.
GSK3b inhibition has been reported to direct hPSC differ-
entiation to blood progenitor (Sturgeon et al., 2014) and
cardiac cells (Lian et al., 2012), supporting its role as a
driver of lateral plate-derived tissues. Our results indi-
cate that mTOR inhibition is an efficient driver of hPSC
differentiation to blood progenitor competent mesoderm.
Comparing the mesendoderm subtypes that emerge in
GSK3b- and mTOR-inhibited differentiation conditions is
an important future direction of our study.
The observation that subnanomolar concentrations of
rapamycin have a moderate enhancing effect on pluripo-
tency correspondswith findings of He et al. (2012) showing
that rapamycin at 0.01 and 0.03 nM enhances mouse so-
matic cell reprogramming efficiency nearly 2-fold while
concentrations of 0.05 nM or greater have no effect or
reduce reprogramming efficiency. Autophagy regulates ho-
meostasis of pluripotency-associated transcription factors
including OCT4 in hPSCs, with autophagy inhibition
increasing transcription factor levels yet leading to differ-
entiation (Cho et al., 2014). Accordingly, low levels of
mTOR inhibition may inhibit autophagy and enhance
OCT4 levels in hPSCs sufficiently to enhance pluripotency,
with higher levels of mTOR inhibition increasing OCT4
levels beyond a threshold to initiate differentiation. Alter-
natively, given that differentiated cell types such as hPSC-
derived extra-embryonic endoderm are known to inhibit
pluripotency (Peerani et al., 2007), it may be that rapamy-
cin selectively inhibits these cell types, leading to increased
hPSC numbers. Another possibility is that the cell-fate ef-
fects of discrete mTOR inhibition levels may be directly
mediated by differential SMAD activation, as mTORC1 in-
hibition activates SMAD1 and SMAD5 in human prostate
cancer cells (Wahdan-Alaswad et al., 2012), and mTORC2
inhibition can enhance SMAD2 and SMAD3 activity
via regulation of the SMAD2/3-T220/T179 linker residue688 Stem Cell Reports j Vol. 6 j 679–691 j May 10, 2016(Yu et al., 2015). Understanding the complex interplay
between discrete levels of mTOR signaling, autophagy,
pluripotency transcription factor homeostasis, signaling
pathway activation, and effects on cell-fate choice and sub-
population dynamics remains an important direction of
future studies.
The methods we present here are applicable to systems
with heterogeneous subpopulations and complex micro-
environmental regulation, such as in vitro stem cell and
cancer models, and can be applied iteratively. Changes in
micro-environmental cues have been attributed to cell-
fate transitions (Bonfanti et al., 2010), and heterogeneity
in micro-environmental context (such as population size,
local cell density, and relative cell position) can determinis-
tically explain phenotypic variance (Snijder et al., 2009).
Improved techniques to control the cellular micro-envi-
ronment in conjunction with improved single-cell ana-
lytics will further develop our understanding of molecular
cell-fate regulation.EXPERIMENTAL PROCEDURES
Cell Culture
We obtained hESC lines H9 (WA09) and H7 (WA07) from the
WiCell Research Institute, and HES3-RUNX1-GFP (HES3-derived
RUNX1-GFP) from A. Elefanty (Monash University). All experi-
ments were performed with H9 unless stated otherwise. These
cell lines were cultured according to previously publishedmethods
(Nazareth et al., 2013). All cell stocks tested negative for myco-
plasma contamination. See Supplemental Experimental Proce-
dures for additional cell line information.
Micro-Patterning hPSCs onto 96-Well Plates and
Application of Small Molecules or Controls
Wepatterned hPSCs onMatrigel into standard 96-well plates as pre-
viously described (Nazareth et al., 2013) (see Supplemental Experi-
mental Procedures). Dissociation of hPSCs was performed using
TrypLE for 3 min. TrypLE was inactivated with medium containing
20% KO-serum replacement (Invitrogen). Cells were centrifuged
and resuspended in NutriStem (NS; StemGent 001-0005) and
10 mM ROCK inhibitor Y-27632. Cells were seeded at 105 cells per
well (or as described in the text) into 96-well plates, coated with
either patterned or non-patterned Matrigel, and incubated for 6 hr.
Cells were then washed twice with PBS and incubated for 42 hr in
fresh test medium (SF supplemented with growth factors or small
molecules, or CM). SF medium consists of DMEM/F12, 13 non-
essential amino acids, 50 U ml1 penicillin, 50 mg ml1 strepto-
mycin, 10 mg ml1 bovine transferrin, 0.1 mM b-mercaptoetha-
nol (all Invitrogen), 2% fatty acid-free Cohn’s fraction V BSA (Sero-
logicals), 13 trace elements A, B, and C (Mediatech), 50 mg ml1
ascorbic acid (Sigma), and 7 mg ml1 recombinant human insulin.
The 400-compound library was obtained from the Ontario Institute
of Cancer Research (OICR) (Tables S2 and S3). The following
control conditions were included on each 96-well plate: blank
(SF medium with no added factors), CM, B (100 ng ml1 BMP4),
BA (10 ng ml1 BMP4 and 100 ng ml1 activin A), and TiF
(40 ng ml1 FGF2 and 10 mM SB431542).Immunocytochemistry and High-Content Image
Analysis
Immunocytochemistry was performed as previously described
(Nazareth et al., 2013; see also Supplemental Experimental Proce-
dures). Single-cell x-y-coordinate and protein-expression data
were exported in tab-delimited text files and imported into in-
house software, ContextExplorer (Joel E.E. Ostblom, E.J.P.N.,
and P.W.Z., unpublished data) for exploration of colony-level de-
tails. For figures, 16-bit TIFF images were obtained for each chan-
nel, identical contrast adjustment was performed on all controls,
and channels were combined into pseudo-colored composite
images.96-Well siRNA Transfection
Human PSCs were first seeded into non-patterned MG-treated
96-well plates at 25,000 cells per well in NS, and incubated for
48 hr. For siRNA transfection, Lipofectamine RNAiMAX transfec-
tion reagent (Invitrogen) was used as per manufacturer’s instruc-
tions, adapted for hPSCs and 96-well plates (see Supplemental
Experimental Procedures).Viability Analysis
To assess viability, we modified the patterned hPSC assay as fol-
lows. Instead of fixing at 48 hr, calcein AM (Invitrogen) (1:1,000)
and Hoechst 33342 (1:1,000) were added directly to the medium,
incubated for 30 min, and then imaged.Differentiation of hPSCs toward Blood Progenitors
and Definitive Endoderm
For ultra-high-throughput production of size-specified cell aggre-
gates, 400-mm diameter micro-well plates (commercially available
as Aggrewells, STEMCELL Technologies) were manufactured in-
house in 24-well plates (Ungrin et al., 2008). For depletion of
MEFs, hPSCs were dissociated with TrypLE and plated onto
Geltrex (diluted 1:50) for 48 hr in NS. After 48 hr, TrypLE was
added for 5 min and then quenched with 50% fetal bovine serum
in DMEM/F12. The resulting single-cell suspension was seeded at
63 105 cells per well of a micro-well plate (500 cells per aggregate)
in the presence of Y-27632 (for 24 hr) at 1,500 rpm for 5 min.
Aggregates were cultured in hypoxia for 8 days in base medium
supplemented with cytokines BMP4 (40 ng ml1, R&D Systems),
vascular endothelial growth factor (VEGF) (50 ng ml1, R&D),
SCF (40 ng ml1, R&D), basic FGF (5 ng ml1, Peprotech), and
rapamycin (0.1 mM, Sigma). Note that rapamycin is highly
labile, and we recommend minimizing freeze-thaw cycles and
titrating for maximum effect. The base medium consists of
StemPro34 (Invitrogen), ascorbic acid (50 mg ml1, Sigma),
L-glutamine (1% v/v, Invitrogen), penicillin/streptomycin (1%
v/v, Invitrogen), 1-monothioglycerol (4 3 104 M, Sigma), and
transferrin (150 mg ml1, Roche). On day 2, hPSC-derived cells
were transferred to low-cluster six-well plates, in medium without
rapamycin, and cultured for an additional 6 days shaken at 85 rpm
(Orbi-Shaker XL, Benchmark Scientific). Endoderm induction toFOXA2+SOX17+ DE was performed as previously described (Reza-
nia et al., 2012).
qRT-PCR
qRT-PCR was performed as described previously (Onishi et al.,
2012). In brief, RNA was isolated using the PureLink RNA Mini
Kit (Ambion) and reverse transcribedwith Superscript III (Life Tech-
nologies). PCRwasperformedon theQuantStudio6Flex (Life Tech-
nologies) using SYBRMaster Mix (Roche) and primers provided by
the Center for Commercialization of Regenerative Medicine. Gene
NCBI-RefSeq accession numbers are provided in Table S4.
CFC Assay
A minimum of 1.5 3 105 cells were seeded on day 8 in 35-mm
Greiner dishes in methylcellulose-based MethoCult H4435
Enriched medium (STEMCELL). Samples were scored based on
morphology 14 days after plating as described by technical man-
uals provided by STEMCELL.
Statistical Analysis
Statistics were computed using one-way ANOVA, two-factor
ANOVA, or linear regression as indicated. All statistics were
computed inMATLABusing p values as indicated.N values are inde-
pendent replicates, not technical replicates, except where noted.
Enrichmentanalysiswasperformedusing thehypergeometricdistri-
bution in Microsoft Excel. Z0 factor was used to assess assay quality
(Zhang et al., 1999). Z0 is defined as Z0 = 1  (3spositive + 3snegative)/
jmpositive  mnegativej, where m and s are the mean and SD of the posi-
tive (CM-treated) and negative (BMP4-treated) control as labeled.
Hierarchical clustering was performed with MeV (MultiExperiment
Viewer,http://www.tm4.org/)usingEuclidandistanceas the similar-
ity metric (centered) and centroid linkage as the clusteringmethod.
Exploratory analysis was performed with Microsoft Excel and
Tableau (Tableau Software, www.tableau.com).
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